Chargement en cours...
Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...
Enregistré dans:
| Publié dans: | Clin Kidney J |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243263/ https://ncbi.nlm.nih.gov/pubmed/34221378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfab062 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|